195 related articles for article (PubMed ID: 30635793)
21. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site.
Pavel M; O'Toole D; Costa F; Capdevila J; Gross D; Kianmanesh R; Krenning E; Knigge U; Salazar R; Pape UF; Öberg K;
Neuroendocrinology; 2016; 103(2):172-85. PubMed ID: 26731013
[No Abstract] [Full Text] [Related]
22. Identification of primary tumors in patients presenting with metastatic gastroenteropancreatic neuroendocrine tumors.
Keck KJ; Maxwell JE; Menda Y; Bellizzi A; Dillon J; O'Dorisio TM; Howe JR
Surgery; 2017 Jan; 161(1):272-279. PubMed ID: 27863780
[TBL] [Abstract][Full Text] [Related]
23. Loss of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine neoplasm.
Wang Y; Chen Y; Li X; Hu W; Zhang Y; Chen L; Chen M; Chen J
BMC Cancer; 2018 Jun; 18(1):691. PubMed ID: 29940892
[TBL] [Abstract][Full Text] [Related]
24. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.
Panzuto F; Merola E; Pavel ME; Rinke A; Kump P; Partelli S; Rinzivillo M; Rodriguez-Laval V; Pape UF; Lipp R; Gress T; Wiedenmann B; Falconi M; Delle Fave G
Oncologist; 2017 Apr; 22(4):409-415. PubMed ID: 28232598
[TBL] [Abstract][Full Text] [Related]
25. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
26. SNM 2012 image of the year.
J Nucl Med; 2012 Oct; 53(10):23N. PubMed ID: 23028181
[No Abstract] [Full Text] [Related]
27. [Gastroenteropancreatic neuroendocrine tumors].
Rayes N; Denecke T
Radiologe; 2021 Dec; 61(12):1129-1138. PubMed ID: 34727206
[TBL] [Abstract][Full Text] [Related]
28. Tumor Macroscopic Morphology Is an Important Prognostic Factor in Predicting Chemotherapeutic Efficacy and Clinical Outcomes of Patients With Colorectal Neuroendocrine Neoplasms, One Multicenter Retrospective Cohort Study.
Wang Z; An K; Li R; Liu Q
Front Endocrinol (Lausanne); 2021; 12():801741. PubMed ID: 34987482
[TBL] [Abstract][Full Text] [Related]
29. Understanding the Treatment Algorithm of Patients with Metastatic Pancreatic Neuroendocrine Neoplasms: A Single-Institution Retrospective Analysis Comparing Outcomes of Chemotherapy, Molecular Targeted Therapy, and Peptide Receptor Radionuclide Therapy in 255 Patients.
Hayes AR; Mak IYF; Evans N; Naik R; Crawford A; Khoo B; Grossman AB; Navalkissoor S; Watkins J; Luong TV; Mandair D; Toumpanakis C; Thirlwell C; Caplin ME; Meyer T
Neuroendocrinology; 2021; 111(9):863-875. PubMed ID: 32950978
[TBL] [Abstract][Full Text] [Related]
30. Bone metastases in neuroendocrine tumors.
Zamborsky R; Svec A; Kokavec M; Galbavy S
Bratisl Lek Listy; 2017; 118(9):529-534. PubMed ID: 29061059
[TBL] [Abstract][Full Text] [Related]
31. Comparative safety review of the current therapies for gastroenteropancreatic neuroendocrine tumors.
Koffas A; Toumpanakis C
Expert Opin Drug Saf; 2021 Mar; 20(3):321-334. PubMed ID: 33338383
[No Abstract] [Full Text] [Related]
32. Endoscopic imaging in the management of gastroenteropancreatic neuroendocrine tumors.
Pellicano R; Fagoonee S; Altruda F; Bruno M; Saracco GM; De Angelis C
Minerva Endocrinol; 2016 Dec; 41(4):490-8. PubMed ID: 27600643
[TBL] [Abstract][Full Text] [Related]
33. Clinical Usefulness of
Rinzivillo M; Partelli S; Prosperi D; Capurso G; Pizzichini P; Iannicelli E; Merola E; Muffatti F; Scopinaro F; Schillaci O; Salgarello M; Falconi M; Delle Fave G; Panzuto F
Oncologist; 2018 Feb; 23(2):186-192. PubMed ID: 29118267
[TBL] [Abstract][Full Text] [Related]
34. Orbital metastases from neuroendocrine neoplasms: clinical implications and outcomes.
Kamieniarz L; Armeni E; O'Mahony LF; Leigh C; Miah L; Narayan A; Bhatt A; Cox N; Mandair D; Navalkissoor S; Caplin M; Toumpanakis C
Endocrine; 2020 Feb; 67(2):485-493. PubMed ID: 31732922
[TBL] [Abstract][Full Text] [Related]
35. Multidisciplinary management of nonfunctional neuroendocrine tumor of the pancreas.
Folkert IW; Hernandez P; Roses RE
World J Gastroenterol; 2016 Mar; 22(11):3105-16. PubMed ID: 27003988
[TBL] [Abstract][Full Text] [Related]
36. Salvage peptide receptor radionuclide therapy with [
van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116
[TBL] [Abstract][Full Text] [Related]
37. Osseous metastases of gastro-enteropancreatic neuroendocrine tumours. Diagnostic value of intra-therapeutic 177Lu-octreotate imaging in comparison with bone scintigraphy.
Sabet A; Ezziddin S; Heinemann F; Guhlke S; Muckle M; Willinek W; Biersack HJ; Ahmadzadehfar H
Nuklearmedizin; 2012; 51(3):95-100. PubMed ID: 22421930
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of multidisciplinary team decisions in neuroendocrine neoplasms: Impact of expert centres.
Zandee WT; Merola E; Poczkaj K; de Mestier L; Klümpen HJ; Geboes K; de Herder WW; Munir A
Eur J Cancer Care (Engl); 2022 Nov; 31(6):e13639. PubMed ID: 35735226
[TBL] [Abstract][Full Text] [Related]
39. [Clinicopathological features of pancreatic neuroendocrine neoplasms: a retrospective analysis of 64 cases].
Yao W; Wang W; Li G
Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):287-93. PubMed ID: 24989916
[TBL] [Abstract][Full Text] [Related]
40. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
Sadowski SM; Neychev V; Millo C; Shih J; Nilubol N; Herscovitch P; Pacak K; Marx SJ; Kebebew E
J Clin Oncol; 2016 Feb; 34(6):588-96. PubMed ID: 26712231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]